Abstract 2831
Background
The early complete morphological remission (CR) after induction chemotherapy is a major independent prognostic factor for both achievements of CR and long-term outcome in acute myeloid leukemia. we studied the correlation between the serum IL-6 levels and the early morphological CR aiming to use serum level of IL-6 instead of invasive painful BM aspiration as a predictive factor for the early response to induction chemotherapy in AML patients.
Methods
During the study period from February 2015 to May 2016, we investigate 36 patients. Eligibility criteria were the evidence of a diagnosis of AML (not AML-M3), both sexes, age of 18-60 years, Patients with a performance status of 0 to 2, and adequate organs functions. We excluded 6 ineligible patients from the study. All patients received induction chemotherapy of cytarabine and anthracycline in the standard “7 + 3” regimen. We did day 14 BM aspiration to detect the presence of early morphological complete remission (≤ 5% marrow blasts) and blood sampling for measurement of the interleukin-6 at presentation and day 14 of starting of induction chemotherapy.
Results
This study included eligible 30 newly diagnosed AML patients with age ranged from 18-60 years (Mean ± SD, 39.53 ± 13.54). The range of marrow blasts at presentation was 20-93% with the Mean ± SD of 58.10% ± 23.10%. As regards the levels of IL-6 at presentation, the mean ± SD was 42.46 ± 28.10 pg/ml and the range was 21.3 - 140.6. Day 14 BMA revealed 8 out of the 30 enrolled patients achieved complete morphological remission (≤ 5 % marrow blasts). There was a statistically significant decrease in IL-6 serum level in patients achieved morphological CR (mean + SD, 18.26 ± 5.75; range, 10.7 - 28.9 pg/ml) than those did not (mean + SD, 26.07 ± 4.78; range, 21.3 - 32.7 pg/ml) (P = 0.017). At Day 14 of induction chemotherapy, there was a significant positive correlation between IL-6 and marrow blasts (r = 0.745, P = 0.000*).
Conclusions
Interleukin-6 is suggested to be a good predictive marker for early response to induction chemotherapy in patients with acute myeloblastic leukemia and may be used instead of invasive day 14 BM aspiration as a marker of this response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Faculty of Medicine, Assiut University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4615 - Proteomic Profiling Identifies Molecular Basis of Adverse Event to BPM31510 Exposure: Rationale for Comprehensive Molecular Pharmacodynamics (PD) in Phase 1 Clinical Trial Design
Presenter: Vivek Subbiah
Session: Poster Display session 1
Resources:
Abstract
5052 - Identification of first-in-class, naturally occurring LAG3 checkpoint inhibitor
Presenter: Gennady Bratslavsky
Session: Poster Display session 1
Resources:
Abstract
5336 - Are Epigenetic therapies modifying sensitivity to conventional chemotherapy?
Presenter: Alexandra Bizot
Session: Poster Display session 1
Resources:
Abstract
5739 - Oncogenic mutations at the dimer interface of EGFR lead to formation of covalent homo-dimers and allosteric activation of the kinase domain: A mechanism which alters the selectivity profile of oncogenic EGFR.
Presenter: Elizabeth Buck
Session: Poster Display session 1
Resources:
Abstract
5492 - Basic selective estrogen receptor degraders (B-SERDs) in combination with novel BET inhibitors in ER+ breast cancer
Presenter: Rui Xiong
Session: Poster Display session 1
Resources:
Abstract
5965 - EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer
Presenter: Ronan Le Moigne
Session: Poster Display session 1
Resources:
Abstract
3582 - AVID200 neutralizes TGF-beta1 and -beta3, the principal immunosuppressive TGF-beta isoforms overexpressed by tumors, and sensitizes tumors to immune checkpoint inhibitors.
Presenter: Tina Gruosso
Session: Poster Display session 1
Resources:
Abstract
1996 - High NAMPT expression and anti-tumor activity of NAMPT inhibitor in adult T-cell leukemia/lymphoma
Presenter: Tomohiro Kozako
Session: Poster Display session 1
Resources:
Abstract
4307 - TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers
Presenter: Alexander Drilon
Session: Poster Display session 1
Resources:
Abstract
4869 - In Vivo Evaluation of Cisplatin-loaded PEG-PCL Block Copolymeric Nanoparticles for Anticancer Drug Delivery
Presenter: Yingtzu Yen
Session: Poster Display session 1
Resources:
Abstract